Drugs / SHR-A1403
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03856541 | Feb → Dec 2019 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-A1403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03856541 ↗ |
| Route | Intravenous | “SHR-A1403 given intravenously (IV).” NCT03856541 ↗ |